Nova Mentis' Psilocybin Preclinical Study Published in International Science Journal
Nova Mentis' Psilocybin Preclinical Study Published in International Science Journal
Microdose Treatment Modulates Cognition
微劑量治療對認知的調節作用
Vancouver, British Columbia--(Newsfile Corp. - December 8, 2022) - Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) ("NOVA" or the "Company"), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders is pleased to announce that its psilocybin preclinical study has been published in the Journal of Psychopharmacology, a fully peer-reviewed, international science journal.
溫哥華，不列顛哥倫比亞省-(Newsfile Corp.-2022年12月8日)-Nova Mentis生命科學公司(CSE：NOVA)(FSE：HN3Q)(OTCQB：NMLSF)(“Nova”或“公司”)，一家生物技術公司和一流的基於裸蓋菇素的療法和神經炎性疾病輔助診斷的全球領導者高興地宣佈，其裸蓋菇素臨床前研究已發表在精神藥理學雜誌，這是一本完全經過同行評審的國際科學期刊。
The article titled 'Psilocybin mitigates the cognitive deficits observed in a rat model of Fragile X syndrome' highlights the data collected during NOVA's preclinical research conducted in the laboratory of Dr. Viviana Trezza, at Rome Tre University, in Rome, Italy.
這篇文章的標題是‘裸蓋菇素減輕脆性X綜合徵大鼠模型的認知缺陷重點介紹了Nova在意大利羅馬大學Viviana Trezza博士的實驗室進行的臨床前研究期間收集的數據。
"Today's announcement gives autism spectrum disorder (ASD) patients and their families hope that NOVA's psilocybin compound (NM-1001) can provide a meaningful impact in the treatment of ASD symptoms, especially cognition," stated Jacqueline McConnell, the Chief Operating Officer of NOVA. "It provides further validation of the significant preclinical research undertaken by NOVA and helps advance our planned Health Canada Phase II A study to evaluate microdose psilocybin therapy in adults with fragile X syndrome (FXS)."
Nova首席運營官傑奎琳·麥康奈爾表示：“今天的聲明給了自閉症譜系障礙(ASD)患者和他們的家人希望Nova的裸蓋菇素化合物(NM-1001)能夠在治療ASD癥狀，特別是認知方面提供有意義的影響。”它進一步證實了Nova公司進行的重要臨床前研究，並有助於推進我們計劃的加拿大衛生部第二階段A研究，以評估對患有脆性X綜合徵(FXS)的成年人的微劑量裸蓋菇素療法。“
The Company's preclinical research substantiates the therapeutic potential of microdosing by demonstrating that a repetitive low dose of psilocybin significantly modulated behavioural and cognitive defects in a genetic model of FXS.
該公司的臨床前研究證明，重複小劑量的裸蓋菇素顯著調節了FXS遺傳模型中的行為和認知缺陷，從而證實了微劑量的治療潛力。
On November 30, NOVA announced that it had submitted to Health Canada the first-ever Phase II A clinical trial application (CTA) testing the safety and efficacy of oral microdose psilocybin therapy for FXS.
11月30日，Nova宣佈，它已經向加拿大衛生部提交了有史以來第一份第二階段A臨床試驗申請(CTA)，測試口服微劑量裸蓋菇素治療FXS的安全性和有效性。
The CTA is subject to a 30-day review by Health Canada, and if approval is granted, NOVA intends to start the clinical study in early 2023. NOVA has completed production of pharmaceutical grade cGMP synthetic psilocybin 1.5 mg microdose capsules that will be used to advance the necessary research and development steps needed for successful drug regulatory approval and future commercialization.
CTA需要接受加拿大衛生部為期30天的審查，如果獲得批准，Nova打算在2023年初開始臨床研究。Nova公司已經完成了藥用級cGMP合成裸蓋菇素1.5 mg微劑量膠囊的生產，這些膠囊將用於推進成功獲得藥品監管部門批准和未來商業化所需的必要研究和開發步驟。
About Nova Mentis Life Science Corp.
關於Nova Mentis生命科學公司
Nova Mentis Life Science Corp. is a Canadian-based biotechnology company and global leader in developing diagnostics and psilocybin-based therapeutics for neuroinflammatory disorders. Nova is the first biotech company to achieve orphan drug designation in both the United States and European Union for the use of psilocybin in the treatment of Fragile X Syndrome (FXS).
Nova Mentis生命科學公司是一家總部位於加拿大的生物技術公司，在開發神經炎性疾病的診斷和基於裸蓋菇素的療法方面處於全球領先地位。Nova是第一家在美國和歐盟獲得使用裸蓋菇素治療脆性X綜合徵(FXS)的孤兒藥物指定的生物技術公司。
Our goal is to diagnose and treat debilitating chronic neuroinflammatory conditions that have unmet medical needs, such as autism spectrum disorder (ASD) and FXS.
我們的目標是診斷和治療尚未滿足醫療需求的衰弱的慢性神經炎性疾病，如自閉症譜系障礙(ASD)和FXS。
For further information on the Company, please visit or email info@novamentis.ca.
欲瞭解更多有關公司的資訊，請訪問或發送電子郵件至info@novamentis.ca。
On Behalf of the Board
我謹代表董事會
Will Rascan, President & CEO
Nova Mentis Life Science Corp.
威爾·拉斯坎，總裁兼首席執行官
Nova Mentis生命科學公司
Phone: 778-819-0244
Toll Free: 1-833-542-5323
電話：778-819-0244
免費電話：1-833-542-5323
Twitter: @novamentislsc
Instagram: @novamentislsc
Facebook: @novamentislsc
推特：@novamentislsc
Instagram：@novamentislsc
臉書：@novamentislsc
Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.
加拿大證券交易所及其市場監管機構(該術語在加拿大證券交易所的政策中定義)均不對本新聞稿的充分性或準確性承擔責任。
This news release contains statements that constitute "forward-looking statements." Such forward looking statements involve known and unknown risks, uncertainties and other factors that may cause Nova Mentis Life Science's actual results, performance or achievements, or developments in the industry to differ materially from the anticipated results, performance or achievements expressed or implied by such forward-looking statements. Forward looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects," "plans," "anticipates," "believes," "intends," "estimates," "projects," "potential" and similar expressions, or that events or conditions "will," "would," "may," "could" or "should" occur.
本新聞稿包含構成“前瞻性陳述”的陳述。此類前瞻性表述涉及已知和未知的風險、不確定性和其他因素，可能導致Nova Mentis生命科學公司的實際結果、業績或成就或行業發展與此類前瞻性表述明示或暗示的預期結果、業績或成就大不相同。前瞻性陳述是指不是歷史事實的陳述，通常但並非總是由“預期”、“計劃”、“預期”、“相信”、“打算”、“估計”、“專案”、“潛在”和類似的表述，或事件或條件“將”、“將”、“可能”、“可能”或“應該”發生。
To view the source version of this press release, please visit
要查看本新聞稿的源版本，請訪問
譯文內容由第三人軟體翻譯。